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Prostate-specific antigen (PSA) is expressed at a
high level in the luminal epithelial cells of the pros-
tate and is absent or expressed at very low levels in
other tissues. PSA expression can be regulated by
androgens. Previously, two functional androgen-
response elements were identified in the proximal
promoter of the PSA gene. To detect additional,
more distal control elements, DNaseI-hypersensi-
tive sites (DHSs) upstream of the PSA gene were
mapped in chromatin from the prostate-derived
cell line LNCaP grown in the presence and absence
of the synthetic androgen R1881. In a region 4.8 to
3.8 kb upstream of the transcription start site of the
PSA gene, a cluster of three DHSs was detected.
The middle DNAseI-hypersensitive site (DHSII, at
;24.2 kb) showed strong androgen responsive-
ness in LNCaP cells and was absent in chromatin
from HeLa cells. Further analysis of the region en-
compassing DHSII provided evidence for the pres-
ence of a complex, androgen-responsive and cell-
specific enhancer. In transient transfected LNCaP
cells, PSA promoter constructs containing this up-
stream enhancer region showed approximately
3000-fold higher activity in the presence than in the
absence of R1881. The core region of the enhancer
could be mapped within a 440-bp fragment. The
enhancer showed synergistic cooperation with the
proximal PSA promoter and was found to be com-
posed of at least three separate regulatory regions.
In the center, a functionally active, high-affinity an-
drogen receptor binding site (GGAACATATTG-
TATC) could be identified. Mutation of this element
almost completely abolished PSA promoter activ-
ity. Transfection experiments in prostate and non-
prostate cell lines showed largely LNCaP cell spec-
ificity of the upstream enhancer region, although
some activity was found in the T47D mammary
tumor cell line. (Molecular Endocrinology 11: 148–
161, 1997)
INTRODUCTION
Prostate-specific antigen (PSA) is a kallikrein-like
serine protease that is almost exclusively synthesized
by the luminal epithelial cells of the human prostate. It
is well known as a prostate tumor marker (1, 2). The
PSA gene is a member of the human kallikrein gene
family. Further members of the kallikrein gene family
are the hGK-1 gene, which is also expressed in the
prostate, and the tissue kallikrein gene (KLK1), which
is expressed in the pancreas and kidney (3–6). The
three genes are clustered in the order [KLK-1]-[PSA]-
[hGK-1], in an area of 60 kb on human chromosome
19q13.2-13.4 (7). The PSA and hGK-1 genes are sep-
arated by 12 kb; the distance between KLK1 and PSA,
which are transcribed from opposite strands, is ap-
proximately 31 kb (7). PSA expression does not only
show cell-specificity, but is also tightly regulated by
androgens, as mediated by the androgen receptor
(AR) (8–12). The strong tissue specificity makes the
PSA promoter a good candidate through which to
deliver therapeutic genes in prostate cancer.
Two functionally active AR-binding sites (androgen
response elements or AREs) were identified in the
proximal PSA promoter, at positions 2170 (ARE-I) and
2394 (ARE-II), respectively (11, 13). Although the
proximal PSA promoter, including ARE-I and ARE-II, is
more active in LNCaP prostate cells than in nonpros-
tate cells, its activity is relatively low. This low level of
activity suggested that the proximal PSA promoter is
not sufficient to account completely for androgen reg-
ulation of the endogenous PSA gene, as observed in
LNCaP cells (11). This indicated to us that additional
cis-acting control elements residing outside the prox-
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imal promoter might contribute to androgen-regulated
PSA gene expression. For several strong, tissue-spe-
cific promoters, like those of the b-globin and tyrosine
amino transferase (TAT) genes, it has been well estab-
lished that important control elements are located in
regions far upstream of the proximal promoter (14–16).
These distal enhancers cooperate with the proximal
promoter for high expression of the specific gene.
To identify putative regulatory elements upstream of
the PSA gene, DNaseI- hypersensitive sites (DHSs)
were mapped in chromatin from LNCaP prostate cells.
Functional analysis of a DNaseI-hypersensitive region
far upstream of the PSA gene showed the presence of
a complex, androgen-regulated enhancer. In this
study we present a detailed analysis of this strong
enhancer, which contains a functionally active, high-
affinity AR-binding site (ARE-III). Furthermore, we
compare the AR-binding affinity and the functionality
of this novel ARE with that of the previously identified
ARE-I and ARE-II (11, 13). An abstract describing parts
of this work has been published previously (17).
While this work was in progress, Schuur et al. (18)
reported the identification of a 1.6-kb upstream en-
hancer fragment (23.7 to 25.3). This fragment encom-
passes the 440-bp core enhancer region, which is the
basis of the present study.
RESULTS
Mapping of DHSs in the PSA Upstream Region
In a previous study we identified two regions in the
PSA proximal promoter that are involved in androgen
regulation (13). A functional active, high-affinity AR-
binding site, ARE-I (AGAACAgcaAGTGCT), was found
to be present at position 2170. ARE-I by itself gave
rise to a weak (2-fold) stimulation of the PSA promoter
activity in the presence of R1881. ARE-I had to coop-
erate with a second, low-affinity AR-binding site,
ARE-II (GGATCAgggAGTCTC) at position 2394 for
maximal (;6-fold) androgen induction of proximal
PSA promoter activity in transfected LNCaP cells.
To identify additional regulatory elements, we
mapped DHSs in the 31-kb region between the PSA
and KLKI genes in chromatin from the prostate-de-
rived cell line LNCaP, grown in the presence and ab-
sence of androgens, and in HeLa cell chromatin. DNA
from DNaseI-treated nuclei was digested with EcoRI
and evaluated for location of DHSs by Southern blot
analysis with the appropriate hybridization probes.
With two different probes, DHSs could be found (Fig.
1). No other DHSs were detected over the 31-kb re-
gion with any of the probes tested (data not shown).
Hybridization of EcoRI-digested DNA from LNCaP
cells with a 1.1-kb HindIII-EcoRI fragment, spanning
exon 1 and intron 1 of the PSA gene, showed one DHS
(DHSIV), which was most prominent in the presence of
R1881 (Fig. 1C). This DHS mapped to the proximal
promoter region. Hybridization of genomic DNA from
R1881-treated LNCaP cells with a 0.5-kb EcoRI-Hin-
dIII probe (26 kb) revealed the presence of a cluster of
three DHSs, approximately 4 kb upstream of the PSA
gene (Fig. 1A). The position of this cluster of DHSs
could be confirmed by hybridization with a more
downstream located probe (data not shown). Analysis
of the same region in chromatin from LNCaP cells
grown in the absence of hormone showed that DHSII
at 24.2 kb is clearly androgen regulated. Intensity of
DHSI, at approximately 24.8 kb, is also influenced by
the presence of R1881 during LNCaP culturing. The
weak DHSIII (at 23.8 kb) could be found both in the
absence and presence of R1881. Although weak,
DHSI and DHSIII might also be present in chromatin
from HeLa cells, which do not express PSA (Fig. 1B).
In contrast, DHSII was clearly absent in HeLa cell
chromatin, indicating cell specificity.
Functional Analysis of the DNaseI-Hypersensitive
Region Upstream of the PSA Gene
To identify the function of the DNA segment containing
the upstream DHSs, a 6-kb PSA promoter fragment
was inserted upstream of the luciferase reporter gene
(PSA-61-LUC), and the activity of this fragment was
compared with that of 2.2-kb (PSA-1-LUC) and
632-bp (PSA-4-LUC) PSA promoter fragments. Tran-
sient transfection to LNCaP cells showed for PSA-61-
LUC a much higher (3000-fold) activity in the presence
than in the absence of R1881 (Fig. 2A). PSA-1-LUC
and PSA-4-LUC gave rise to a 6-fold and 4-fold in-
duction, respectively, upon hormone treatment. These
experiments clearly indicated the presence of a very
potent enhancer between 26 and 22.2 kb.
To map this upstream region in more detail, a 2.2-kb
XbaI-StuI fragment (see Fig. 2B for a partial restriction
map of the PSA promoter), encompassing the three
upstream DHSs, was inserted in front of the proximal
PSA promoter in PSA-4-LUC, which starts at the
EcoRI site at 2632 and contains ARE-I (2170) and
ARE-II (2394) (13) (Fig. 3A), giving rise to construct
PSA-64-s-LUC. Transfection of PSA-64-s-LUC to LN-
CaP cells resulted in an even higher (.6000-fold) in-
duction of promoter activity upon R1881 activation
(Fig. 3A), indicating that the upstream enhancer activ-
ity resides within this 2.2-kb fragment. The 2.2-kb
XbaI-StuI fragment in the opposite orientation gave
rise to a similar high activity (PSA-64-as-LUC in Fig.
3A).
To determine the borders of the upstream enhancer
region, a series of truncated fragments was linked to
the proximal PSA promoter in LUC reporter gene con-
structs. Both PSA-73-LUC (1-kb PstI-BamHI) and
PSA-74-LUC (0.9-kb PstI-PstI) showed an induction
and absolute activity, which was approximately 50%
of PSA-64 activity. A further 200-bp 39-truncation in
construct PSA-78-LUC (PstI-EcoRV) resulted in a
4-fold decrease in activity upon R1881 treatment.
Similarly, deletion of the distal end (PSA-83-LUC) re-
sulted in an 8-fold reduction in activity. The 440-bp
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BstEII-PstI fragment (PSA-85-LUC) turned out to be
the smallest fragment with strong enhancer activity
(Fig. 3A). We defined the BstEII-PstI fragment as the
core enhancer. The sequence of this core enhancer is
shown in Fig. 3B. Because further 59- or 39- deletion
resulted in a partial decrease of core enhancer activity,
two or more separate enhancer elements must be
present in this fragment. Most accurate calculations of
the positions of DHSI, -II, and -III showed that DHSII is
located within the core enhancer fragment; however,
this is not the case for DHSI and DHSIII. Most likely,
DHSI is situated close to the PstI site at 24.8 kb, and
DHSIII is located close to the BamHI site at 23.8 kb
(see Fig. 2B).
To determine whether core enhancer activity was
directly androgen regulated, the BstEII-PstI fragment
was linked in both orientations to the TK promoter
(TK-85-s-LUC and TK-85-as-LUC, respectively), and
LNCaP cells were transfected with these constructs
(Fig. 3C). The result clearly showed that this 440-bp
fragment contained orientation-independent, intrinsic
androgen- responsive enhancer activity. This obser-
vation correlated with the strong androgen regulation
of DHSII, linking results of the transient transfection
studies with the activity of the promoter of the endog-
enous PSA gene. Additionally, the results indicated
synergistic cooperation between the upstream en-
hancer and the proximal PSA promoter, because PSA-
61-LUC and PSA-85-LUC were considerably more ac-
tive than TK-85-LUC (Figs. 2A and 3, A and C, and
data not shown).
Identification of an ARE in the Core Enhancer
Region
To identify candidate AR-binding sites, DNaseI foot-
prints were determined over four overlapping core en-
hancer segments, utilizing the purified AR DNA-bind-
ing domain (AR-DBD). The only clear protection that
was observed was located in the middle part of the
fragment, over the sequence 59-ACTCTGGAGGAA-
CATATTGTATCGATT-39, directly upstream of the ClaI
Fig. 1. DHSs in Chromatin Upstream of the PSA Gene
Southern blot analysis of genomic DNA from nuclei of LNCaP (A and C) and HeLa (B) cells incubated with increasing amounts
of DNaseI (lanes 2–7 and 9–14 in panel A; 2–6 in panel B; and 2–7 and 9–14 in panel C; lanes 1 and 8 in panel A, lane 1 in panel
B, and lanes 1 and 8 in panel C are controls without DNAseI treatment), and digested with EcoRI. Hybridization was with an
EcoRI-HindIII probe at 26 kb (A and B) or a HindIII-EcoRI probe at 11 kb (C). Nuclei were isolated from LNCaP cells grown in
the absence (panel A, lanes 1–7; panel C, lanes 1–7) or presence of R1881 (panel A, lanes 8–14; panel C, lanes 8–14), or from
HeLa cells grown in 5% complete FCS (panel B). D, Schematic representation of the PSA gene. Black squares represent the five
exons of the PSA gene. Hybridization probes are indicated by horizontal bars in the partial restriction map. Positions of DHSs are
indicated by arrows (DHSI-IV).
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site (Fig. 4A). The protected area contained the se-
quence GGAACAtatTGTATC, which shows high ho-
mology (overall 9 of 12 bp), with the consensus se-
quence GGT/AACAnnnTGTTCT for high-affinity AR
binding (19). Competition was found with a 100-fold
excess ARE consensus oligo, but not with an excess
of an NF-1 consensus oligo (Fig. 4A, lanes 4 and 5),
indicating specificity of the interaction. Although both
the BstEII-SalI and EcoRV-PstI subfragments contrib-
uted to maximal activity of the core enhancer (Fig. 3A),
AR binding was not observed in one of these frag-
ments (data not shown). Gel retardation analysis of a
double-stranded oligonucleotide encompassing the
upstream AR-binding site (ARE-III: ggaGGAACAtatT-
GTATCgat) with AR-DBD confirmed that this fragment
contains a specific, high-affinity AR-binding site (Fig.
4B).
To test whether ARE-III was functionally active, the
sequence was mutated to GCATAAtatTTCAAC in TK-
85-s-LUC, resulting in construct TK-85-I-LUC. In
transfection experiments, the mutated enhancer was
no longer R1881 inducible (Fig. 4C). This not only
indicated that ARE-III was functionally active, but also
provided evidence for a pivotal role of ARE-III in an-
drogen regulation by the core enhancer region.
Comparison of ARE-I, ARE-II, and ARE-III
The presence of (at least) three AREs [ARE-I(2170):
AGAACAgcaAGTGCT; ARE-II(2394): GGATCAgg-
gAGTCTC, and ARE-III (24200): GGAACAtatTGTATC]
in the PSA promoter raised the question of relative
AR-binding affinities of the individual AREs and their
separate contribution to overall androgen regulation of
PSA promoter activity. To compare AR binding to
these AREs, gel retardation analyses were performed
with serial dilutions of purified AR-DBD (Fig. 5A). ARE-I
and ARE-III turned out to be high-affinity AR-DBD-
binding sites, with comparable AR-binding affinity.
Fig. 2. Androgen Regulation of the PSA Promoter in LNCaP Cells
A, LNCaP cells were transiently transfected with PSA-LUC constructs as described in Materials and Methods. After 4 h
incubation with the plasmid precipitate, transfected cells were cultured for 24 h in the absence or in the presence of R1881 (1 nM).
The absolute activity and relative induction factor were calculated as the mean of four or more independent experiments, which
were done in duplicate. Solid bar, Activity in the presence of R1881; open bar, activity in the absence of R1881. The SEM of the
absolute activity is represented by a horizontal stripe. The induction level is indicated at the right side of the bars. Positions of
ARE-I and ARE-II in PSA promoter constructs are represented by black squares. Positions of DHS I, II, and III are indicated by
arrows. B, Partial restriction map of the PSA promoter. “SalI” represents the position of an artificial SalI site derived from the
border of a human genomic DNA fragment in l EMBL3.
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Fig. 3. Identification of the Androgen-Regulated Core Enhancer Region, Upstream of the PSA Gene
A, Detailed deletion mapping of the upstream region of the PSA gene in transfected LNCaP cells. Experimental details of the
transfections are described in Materials and Methods and in the legend to Fig. 2A. The activity of the PSA-61-LUC construct in
the presence of R1881 is set at 100%. The mean of the luciferase activity and the relative induction levels are from at least four
independent experiments. B, Sequence of the 440-bp BstEII-PstI upstream core enhancer fragment. Important restriction sites
are indicated above the sequence. The ARE-III sequence is underlined, with the two half-sites in capital letters. C, Effect of the
core enhancer region on TK promoter activity in LNCaP cells. The hatched box represents the 440-bp core enhancer. Experi-
mental details are as in Fig. 2A.
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Fig. 4. Identification of a Functionally Active AR-Binding Site in the Core Enhancer Region
A, DNAseI footprint analysis over ARE-III. The lower strand of pHS2 (“SalI”-EcoRV fragment in the core enhancer) was
32P-end-labeled, digested with DNaseI in the absence (lanes 1 and 6) and presence of 10 (lane 2) and 20 pmol (lanes 3–5) AR(DBD)
fusion protein, and subjected to gel electrophoresis (see Materials and Methods). Lanes 4 and 5, Competition with a 100-fold
excess double-stranded nonspecific (NF-1 consensus oligo, lane 4), and specific oligonucleotide (ARE consensus, lane 5).
Maxam and Gilbert sequence reactions are run alongside the footprint (G and G1A). The sequence of the protected area is
depicted at the right. The two ARE-III half-sites are in capital letters. LS, Lower strand; US, upper strand. B, Gel retardation
analysis of the ARE-III*AR(DBD) complex. Experimental details are as described in Materials and Methods. Lane 1, Free ARE-III
probe; lanes 2–5, ARE-III probe incubated with AR(DBD). Lanes 3–5, Competition with a 100-fold excess ARE-III oligo (lane 3),
ARE consensus oligo (lane 4), and NF-1 consensus oligo (lane 5). The arrow indicates the position of the AR-III*AR(DBD) complex.
The ARE-III sequence is presented below the figure. C, The effect of ARE-III inactivation on the androgen-regulated core enhancer
activity in transiently transfected LNCaP cells. Experimental details are as described in Materials and Methods and in the legend
to Fig. 2A. Solid bar, Activity in the presence of R1881 (1 nM); open bar, activity in the absence of hormone. Mean values of
luciferase activities and induction levels, and the SEM (horizontal stripe) are from three independent, duplicate experiments. The
hatched bar in the constructs represents the core enhancer. ARE-III is given as a black square. The inactivated ARE-III is
represented by a cross.
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Fig. 5. Comparison of ARE-I, ARE-II, and ARE-III in Vitro AR(DBD) Binding and Functional Activity
A, Gel retardation analysis of ARE-I, ARE-II, and ARE-III complexed with AR(DBD). ARE-1 (lanes 1–5), ARE-II (lanes 6–10), and
ARE-III (lanes 11–15) (50 3 103 cpm) are incubated with an increasing amount of AR(DBD) and analyzed by gel retardation assay
as described in Material and Methods. Lanes 1, 6, and 11, Free probe. Lanes 2, 7 and 12, 30 fmol AR(DBD). In each panel, the
following lane contains four times more AR(DBD). The arrow indicates the position of the ARE*AR(DBD) complex. ARE-I, ARE-II,
and ARE-III sequences are presented below the figure. B, Effect of ARE-I, ARE-II, and ARE-III on minimal TK promoter activity
in transiently transfected LNCaP cells. LNCaP cells were cotransfected with the indicated reporter gene construct and the AR
expression vector pSVARo (2.5 mg). The ARE fragments are represented by triangles; mean values and SEM are from three
independent, duplicate experiments. Further experimental details are described in Materials and Methods and in the legend to Fig.
2A.
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The in vitro interaction of AR-DBD with ARE-II was
much weaker.
Next, three copies of ARE-III were inserted in front of
the minimal TK promoter in TK-LUC, and the activity
was compared with similar ARE-I and ARE-II TK-LUC
constructs. Transient transfection experiments in LN-
CaP cells showed ARE-III to be functionally active,
albeit less than ARE-I: 10-fold and 34-fold induction
upon R1881 stimulation, respectively (see Fig. 5B).
However, both ARE-I and ARE-III were more active
than ARE-II.
Mutational Analysis of ARE-I, -II, and -III
To investigate the role of the individual AREs in overall
androgen- induced transcriptional responsiveness of
the 6-kb PSA promoter, for each individual ARE two
different knock out mutations were introduced in PSA-
61-LUC (see Materials and Methods for sequences of
mutated AREs). Transient transfection of LNCaP cells
with the resulting mutated PSA promoter-LUC con-
structs showed that all three AREs contributed to an-
drogen regulation. ARE-I(2170) mutations resulted in
an 80% reduction of promoter activity (Fig. 6). Both
mutations in ARE-II(2394) had a limited effect (50% or
less reduction). Mutations in ARE-III had by far the
most dramatic effect. As compared with wild type
PSA-61-LUC, less than 1% of activity was retained in
the mutated promoter. This finding indicated that
ARE-III is not only a key element in the 440-bp up-
stream core enhancer, as shown in Fig. 4C, but also in
the context of the 6-kb PSA promoter.
Tissue Specificity of the PSA Promoter
Previous work in our laboratory showed that the prox-
imal PSA promoter is more active in LNCaP prostate
cells than in nonprostate cells (13). To study whether
the androgen-induced activity of the upstream core
enhancer also showed cell specificity, reporter con-
structs PSA-61-LUC (Fig. 2), TK-85-s-LUC, and the
TK-LUC control (Fig. 3C) were cotransfected with the
AR expression plasmid pSVARo to a series of AR-
negative prostate and nonprostate cell lines. In con-
trast to the high activity in LNCaP cells, TK-85-s-LUC
showed hardly any activity over basal TK promoter
activity in the androgen-independent prostate cell
lines PC-3 and DU145 and in COS (monkey kidney)
and Hep3B (human hepatoma) cells (Table 1). Further-
more, the 6-kb PSA promoter was hardly active in
these cells. For comparison, MMTV-LUC was trans-
fected to the same set of cell lines. In PC3 and DU145
cells, a low R1881-induced activity was detected. In
COS, Hep3B, and LNCaP cells, the MMTV promoter
was strongly induced. Interestingly, in COS and HeLa
cells, induction of MMTV promoter activity was 40–60
times higher than that of PSA-61. In contrast, in LN-
CaP cells, PSA-61-LUC was 6 times more active than
MMTV-LUC. These findings clearly indicate cell spec-
ificity of the PSA promoter.
The only tested cells, other than LNCaP cells, in
which the PSA promoter was active was the human
mammary carcinoma cell line T47D. Transfection of
TK-85-s-LUC to T47D cells resulted in a 25-fold in-
duction of luciferase activity upon R1881 stimulation,
even in the absence of pSVARo cotransfection (Table
Fig. 6. The Effect of the Inactivation of ARE-I, ARE-II, and ARE-III on Androgen Regulation of the PSA Promoter
Experimental details are as described in Materials and Methods and in the legend to Fig. 2A. PSA-61-LUC activity in LNCaP
cells cultured in the presence of R1881 is set at 100%. The ARE mutations in the 6 kb PSA-61-LUC construct are indicated by
crosses. Mean values and SEM are from four independent, duplicate experiments. Hormone induction values are given at the right
side of the bars.
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2A). PSA-61-LUC could be stimulated approximately
100-fold by R1881. Because T47D cells are known to
contain the progesterone receptor (PR) and a low level
of AR, and because R1881 can activate both AR and
PR, experiments were repeated with the pure andro-
gen dihydrotestosterone (DHT) and the pure progestin
R5020. DHT stimulation of T47D cells transfected with
TK-85-s-LUC and PSA-61-LUC resulted in a 4-fold
and 15-fold induction of LUC activity, respectively.
R5020 stimulation of T47D cells transfected with TK-
85-s-LUC and PSA-61-LUC gave rise to induction lev-
els, comparable to R1881 stimulation. Cotransfection
of T47D cells with pSVARo slightly increased DHT-
induced PSA promoter activity (Table 2B). These re-
sults indicate that the PSA promoter is not completely
cell specific and, also, that PSA promoter activity is
not completely AR specific. However, comparison of
PSA (PSA-61 and TK-85) and MMTV promoter activity
in T47D cells with that in LNCaP cells (Tables 1 and 2)
still indicates a strong preference of the PSA promoter
for LNCaP cells.
DISCUSSION
It is well established that PSA expression is directly
androgen regulated and cell specific. Previously, in
transient transfection experiments with PSA promoter
constructs, combined with in vitro protein-DNA inter-
action assays, two AREs were identified in the proxi-
mal PSA promoter: ARE-I at position 2170, and ARE-II
at 2394 (11, 13). Activity of a 632-bp proximal pro-
moter was approximately 6-fold induced by R1881 in
LNCaP cells. Cotransfection with an AR or glucocor-
ticoid receptor (GR) expression plasmid resulted in an
increase of absolute activity and induction level of the
proximal promoter upon R1881 treatment. The low
level of induction obtained with the endogenous AR
suggested that the proximal PSA promoter was not
sufficient to account completely for the androgen in-
duction as observed for the endogenous PSA gene
(11). In the present study we characterized a strong
upstream enhancer, which is required for high, andro-
gen-regulated and cell- specific expression of the PSA
gene. The results described extend our own previous
work and the recent work of Schuur et al. (18). As
compared with the latter study, two major differences
seem obvious: 1) In the experiments described in the
present study, approximately 50% of the activity of the
upstream enhancer region is retained within the
440-bp BstEII-PstI (24.3 to 23.9) fragment (see Fig.
3A), whereas in the work of Schuur et al. essentially all
activity is lost by deletion of sequences downstream of
the XbaI site at 25.3 kb. At the 39-border of the en-
hancer region the differences are less dramatic. Dele-
tion from the PstI site to the EcoRV site in constructs
PSA-73 and PSA-74 results in an approximately 5-fold
loss of activity (see Fig. 3A); the comparable con-
structs in Ref. 18 (CN70 and CN71) show a 2-fold
decrease in activity. In summary, we found the minimal
region with high enhancer activity to be approximately
1 kb smaller at the 59-border. Although it can always
be argued that different LNCaP sublines and culture
conditions have been used, there is no obvious expla-
nation for the differences observed. 2) A second dif-
ference between the data in Ref. 18 and our findings
Table 2. Effect of R1881, DHT, and R5020 on PSA-61-LUC, TK-85-LUC, and MMTV-LUC Activity in T47D Cells, without (A)
and with Cotransfection of the AR Expression Plasmid pSVARo (B)
Construct
Relative Induction (1/2 Hormone)a
A R1881 DHT R5020 B DHT
TK-85-s-LUCb 25 6 4 4.3 6 0.4 26 6 3 8.2 6 1.7
TK-LUC 1.3 6 0.2 1.1 6 0.2 1.1 6 0.1 1.3 6 0.3
PSA-61-LUC 97 6 21 17 6 4 157 6 29 25 6 7
MMTV-LUC 504 6 50 228 6 21 512 6 60 478 6 45
a Induction is the mean of three independent, duplicate experiments 6 SEM.
b Constructs are described in Materials and Methods.
Table 1. Effect of R1881 on PSA-61-LUC, TK-85-LUC, and MMTV-LUC Activity in PC3, DU145, COS, and Hep3B Cells,
Cotransfected with the AR Expression Plasmid pSVARo, as Compared to LNCaP Cells
Construct
Relative Induction (1/2 R1881)a
PC3 DU145 COS Hep3B LNCaP
TK-85-s-LUCb 1.5 6 0.2 1.2 6 0.1 1.8 6 0.3 1.3 6 0.4 163 6 17
TK-LUC 1.5 6 0.2 1.1 6 0.3 1.3 6 0.4 1.1 6 0.3 1.4 6 0.2
PSA-61-LUC 1.7 6 0.5 1.2 6 0.1 1.4 6 0.3 2.1 6 0.8 3000 6 224
MMTV-LUC 2.8 6 1.5 2.6 6 0.9 58 6 20 115 6 36 476 6 64
a Induction is the mean of three independent, duplicate experiments 6 SEM.
b Constructs are described in Materials and Methods.
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concerns the induction level of the 6-kb PSA promoter
(3000 as compared with 38). Part of the difference in
induction might be accounted for by the reporter
genes used (LUC and CAT, respectively). The higher
sensitivity of the LUC assay enabled us to compare
the properties of ARE-III in the upstream enhancer
with those of ARE-I and ARE-II in the proximal
promoter.
An important goal of the present study was the
analysis of the chromatin structure in a 31-kb region
upstream of the PSA gene by the identification of
DHSs. Although other explanations are possible,
DHSs in chromatin, which reflect structural alterations,
are a strong indication for the interruption of the nu-
cleosome structure due to binding of transcription fac-
tors to the DNA. In chromatin from LNCaP cells, three
DHSs were found clustered in the area from 3.8 to 4.8
kb upstream of the PSA gene. DHSIII (at 23.8 kb) is
weak and also present in chromatin from HeLa cells,
which do not express PSA. DHSI (at 24.8 kb) is clearly
androgen induced in LNCaP cells. DHSII (at 24.2 kb)
is by far the most prominent: it is strongly androgen
induced in LNCaP cells and absent in HeLa cells. The
differences in structure between chromatin from LN-
CaP cells, grown in the presence and absence of
R1881, and from HeLa cells indicated to us a func-
tional role of the DHS cluster in androgen-regulated
and cell-specific expression of the endogenous PSA
gene.
In transient transfection experiments, the 24.8 to
23.8 region showed strong, androgen-regulated en-
hancer activity (PSA-64-s-LUC and PSA-64-as-LUC in
Fig. 3A). It is not clear whether sequences correspond-
ing to DHSI and DHSIII are present in the shorter active
enhancer construct PSA-73-LUC. Most likely, DHSI
maps very close to the PstI site, which is at the 59-
border of PSA-73-LUC; DHSIII maps close to the
BamHI site, which determines the 39-border of PSA-
73-LUC. An even shorter fragment, PSA-85-LUC,
lacks both DHSI and DHSIII, but contains DHSII, which
maps close to the ClaI site. The finding that PSA-85-
LUC still shows approximately 50% of the enhancer
activity suggests that, in transient transfections, DHSI
and DHSIII sequences play no or only a minor part in
PSA promoter activity. Whether they are required for
proper expression of the endogenous PSA gene re-
mains to be determined. The finding that ARE-III at
24.2 kb corresponds to DHSII in the chromatin sug-
gests that ARE-III is not only essential in the PSA
promoter in transient transfections, but also in andro-
gen-regulated expression of the endogenous PSA
gene.
The upstream core enhancer most probably has a
complex structure. We were unable to narrow down
the size of the core enhancer to less than 440 bp
without loosing substantial activity. Combined with the
essential role of ARE-III in the enhancer, at least three
separate active regions can be identified in the core
enhancer: ARE-III, and the 59- and 39-end fragments
(see Fig. 3). In each of the two end fragments, one or
more binding sites of ubiquitous or prostate-specific
transcription factors might be located. The possibility
that these fragments contain one or more weak, so far
not identified, AR-binding sites cannot be excluded. In
cooperation with ARE-III, and additional cis-acting se-
quences within the 130-bp SalI-EcoRV fragment, a
complex enhancer might be formed with cooperative
interactions between the different components. Fur-
ther experiments are obviously required to elucidate
the detailed composition of this core enhancer.
A functional ARE-III is a prerequisite for high activity
of the upstream enhancer. Inactivation of ARE-III al-
most completely abolished core enhancer activity. In
contrast, truncation of the 59- and 39-fragments re-
sulted only in a partial reduction of enhancer activity.
However, there is little doubt about a synergistic co-
operation of ARE-III with other cis-acting elements in
the core enhancer: when attached to the TK promoter,
the core enhancer, containing one ARE-III, is superior
to even three copies of ARE-III coupled to the TK
promoter. A mechanism explaining the central role of
ARE-III could be AR-induced DNA bending, enabling
the direct or indirect interaction between other tran-
scription factors in the core enhancer. Alternatively,
ARE-III-bound AR might be a key element in the inter-
action of the upstream enhancer with the proximal
promoter region or in the recruitment of the RNA poly-
merase II holoenzyme to the PSA promoter (20, 21). In
this respect the PSA upstream enhancer might func-
tion as a classic complex, steroid hormone- regulated
control region. Similar upstream glucocorticoid-regu-
lated enhancers, composed of GR-binding sites, bind-
ing sites for the liver-enriched transcription factors
HNF-3 and HNF-4, and binding sites for more ubiqui-
tous transcription factors, have been identified for the
TAT gene, which is highly expressed in liver parenchy-
mal cells (15, 16). The enhancer motifs restrict the
hormonal activation of the TAT gene to liver cells, not
only in cultured cells, but also in transgenic mice (22).
The PSA gene is the first example of an androgen-
regulated, prostate-specific gene for which such a
potent upstream enhancer is documented. Further
study of this enhancer may be of great help in the
identification of prostate-specific transcription factors
and in the elucidation of the mechanism of cooperative
interaction between the AR and other transcription
factors.
The identification of three AREs in the PSA promoter
in the present and in our previous studies (11, 13)
readily raised the question of relative AR- binding af-
finities and functional activities. ARE-I and ARE-III
were found to be of similar potency, whereas ARE-II
was less active. Mutational analysis indicated a clear
synergistic cooperativity between ARE-I and ARE-III
and, to a lesser extent, ARE-II. However, inactivation
of ARE-III had a far more impressive effect on the 6-kb
PSA promoter than mutation of ARE-I. From these
findings it can be concluded that the context in which
the ARE is present has a pivotal effect on its functional
activity. As indicated above, this might involve inter-
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actions with other transcription factors, including the
spacing between specific cis-acting elements.
Although the PSA gene is the first example of a gene
containing a very potent far upstream ARE, clear syn-
ergistic interaction between multiple ARE sequences
has also been found in the proximal (600-bp) PSA
promoter (see Ref. 13, as discussed above) and in the
proximal (426-bp) prostate-specific rat probasin (PB)
promoter (23). Both the proximal PSA and the PB
promoter contain one high-affinity and one low-affin-
ity, functionally active AR-binding site (13, 23). Al-
though much more active in their natural setting, mul-
timers of the different, separate AREs from the PSA
promoter are functionally active when fused to a het-
erologous promoter (Fig. 5B, and Ref. 13). In contrast,
cooperative binding of the AR to both AREs in the PB
promoter is required for androgen induction (24).
To investigate cell specificity of PSA upstream core
enhancer, we compared its activity in several prostate
and nonprostate cell lines. Transient transfection ex-
periments in (PSA negative) PC3, DU145, Hep3B, and
COS cells did not reveal any activity, although two of
the cell lines (PC3, DU145) originate from a prostate
background. The MMTV promoter showed a very lim-
ited activity in AR-cotransfected PC3 and DU145 cells,
but was clearly active in COS and HeLa cells. Together
these findings indicate the absence of one or more
transcription factor(s) or coactivator(s) essential for
PSA promoter activity in these cells. Alternatively, a
specific inhibitor of PSA promoter activity is present.
The specificity of DHSII provided additional evidence
for cell-specific activity of the PSA promoter.
TK-85-LUC and PSA-61-LUC were both found to be
active in T47D cells. In T47D cells, PSA promoter
activity was not only mediated through the AR but also
via the PR (Table 2). These results indicate that activity
of the 6-kb PSA promoter is not entirely prostate- and
androgen-specific. However, PSA promoter activity in
LNCaP cells is superior to T47D cell activity. The issue
of receptor specificity should be investigated in more
detail in cell lines containing comparable amounts of
PR and AR, either endogenously or after cotransfec-
tion with the respective steroid receptor expression
plasmid. In a similar type of experimental setup, we
generated LNCaP sublines containing a stable trans-
fected GR expression plasmid. This resulted in dexa-
methasone induction of the endogenous PSA gene
and GR-regulated activity of the 6-kb PSA promoter in
transient transfections (K. B. J. M. Cleutjens, in prep-
aration). In summary, steroid hormone-regulated ex-
pression of the PSA promoter depends on the prop-
erties of the cell line: the presence of AR, PR, or GR is
an essential, but not the only, factor. Absence of spe-
cific inhibitors or presence of additional transcription
factors and/or coactivators will also be essential.
Although PSA expression was originally thought to
be strictly restricted to prostate epithelial cells, low
PSA expression in mammary tumor cells has been
recently published (25, 26). The activity of the PSA
promoter in transfected T47D cells, which are negative
on Northern blots for endogenous PSA expression,
could be in accordance with these findings. It would
be of interest to determine whether, in mammary tu-
mor tissue, PSA expression is progesterone regulated
and could be used as a reliable marker for PR-positive
tumors. To obtain more definite information on tissue
specificity of the 6-kb PSA promoter in both normal
and tumor cells, animal studies with PSA promoter
constructs are required. If the upstream enhancer is
able to confer preferential expression of a target gene
to prostate cells, in vivo applications in humans, in-
cluding gene therapy for delivery of pharmaceutical
reagents to the prostate, can be further explored.
MATERIALS AND METHODS
Cell Culture
LNCaP cells (FGC), originally obtained from Dr. Horoszewicz
(27), were cultured in RPMI 1640 and supplemented with 5%
FCS and antibiotics. For transfection, cells were grown in
DMEM supplemented with 5% steroid-depleted (dextran-
charcoal treated) FCS. For examination of androgen-induced
DHSs and androgen-driven promoter activity in transfection
experiments, the synthetic androgen R1881 (DuPont NEN,
Boston, MA) was added to a final concentration of 1 nM. In
indicated cases, DHT (Steraloids, Wilton, NH) and R5020
(DuPont NEN) were added to final concentrations of 100 nM
and 10 nM, respectively.
HeLa, T47D, and COS cells were grown in DMEM; Hep3B
cells were grown in MEMa, supplemented with 5% FCS and
antibiotics. PC3 and DU145 cells were grown in RPMI 1640,
supplemented with 7.5% FCS and antibiotics. For transfec-
tion, PC3 and DU145 cells were grown in DMEM.
Mapping of DHSs
Cultured cells (LNCaP cells, grown in the presence and ab-
sence of 1 nM R1881, and HeLa cells) were washed with
ice-cold PBS. Cells were suspended in 3 ml ice-cold HS
buffer (15 mM Tris-HCl, pH 7.4, 60 mM KCl, 15 mM NaCl, 0.2
mM EDTA, 0.2 mM EGTA, and 5% glycerol, supplemented
with 1 mM dithiothreitol, 0.15 mM spermine, and 0.5 mM
spermidine, directly before use). The cells were disrupted by
passing five to 10 times through a 0.5 3 16 mm (25G) needle.
Disruption was monitored by light microscopic examination.
Nuclei were collected by centrifugation for 5 min at 2500 rpm
and resuspended in HS buffer to a final concentration of 5 3
107 nuclei/ml. Limited DNaseI digestion was carried out in a
final volume of 0.5 ml HS buffer containing 5 3 106 nuclei, 5
mM MgCl2, and DNaseI (0–800 U; Boehringer Mannheim,
Mannheim, Germany). The mixture was incubated for 30 min
on ice, and the reaction was stopped by addition of 10 ml 0.5
M EDTA, 12.5 ml 20% SDS, and 50 ml Proteinase K (10
mg/ml). Next, the sample was incubated overnight at 37 C.
Subsequent to phenol/chloroform extraction, the DNA was
collected by isopropanol precipitation. The DNA was dis-
solved in 100 ml Tris-EDTA buffer and digested with EcoRI.
Restriction fragments were separated by electrophoresis in a
1% agarose gel and transferred to a nylon membrane (Hy-
bond N1, Amersham, Cardiff, UK). Filters were hybridized at
high stringency with random primed 32P-labeled probes (as
indicated in Fig. 1) using standard procedures (28).
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Construction of Plasmids
All plasmid constructs were prepared using standard meth-
ods (28). The promoterless basic plasmid pLUC, PSA-4-LUC,
TKLUC, the human AR expression plasmid pSVARo, the
AR(DBD) expression plasmid pRIT2TAR, and pMMTV-LUC
were described previously (13, 29–31). PSA-61-LUC was
generated by insertion of the HindIII/HindIII (26 kb/112) frag-
ment of the PSA promoter in the multiple cloning site (MCS)
of pLUC. PSA-1-LUC was generated by ligation of the
BamHI/HindIII (22.2 kb/112) fragment in the MCS of pLUC.
PSA-64-s-LUC and PSA-64-as-LUC (XbaI-StuI, 25.4/23.2
kb), PSA-73-LUC (PstI-PstI, 24.7/23.9 plus PstI-BamHI
23.9/23.8 kb), PSA-74-LUC (PstI-PstI, 24.7/23.9 kb), PSA-
78-LUC (PstI-EcoRV, 24.8/24.1 kb), PSA-83-LUC (SalI-
BamHI, 24.25/23.8 kb), and PSA-85-LUC (BstEII-PstI,
24.35/23.9 kb) were generated by insertion of the appropri-
ate fragments in front of the proximal PSA promoter (2632/
112) in construct PSA-4-LUC. The artificial SalI site (24.25
kb) was derived from the 59-end of a human genomic DNA
phage insert (4P1, see Ref. 7).
Constructs TK-85-s-LUC and TK-85-as-LUC were gener-
ated by insertion of the 440-bp BstEII-PstI fragment into the
MCS of TKLUC. Constructs ARE-I-TKLUC and ARE-III-TK-
LUC were generated by cloning three copies of ARE-I and
ARE-III oligonucleotides in TKLUC, respectively (sequences
of oligonucleotides are shown below). ARE-II-TKLUC was
generated by ligation of the double-stranded 3ARE-II oligo-
nucleotide in the SalI site of TKLUC.
ARE-I: 59 GATCCTTGCAGAACAGCAAGTGCTAGCTG 39
39 GAACGTCTTGTCGTTCACGATCGACCTAG 59
3ARE-II: 59 TCGACAGGGATCAGGGAGTCTCACCAGGGATCA-
39 GTCCCTAGTCCCTCAGACTGGTCCCTAGT-
GGGAGTCTCACCAGGGATCAGGGAGTCTCACG 39
CCCTCAGAGTGGTCCCTAGTCCCTCAGAGTGCAGCT 59
ARE-III: 59 TCGACGAGGAACATATTGTATCGAG 39
39 GCTCCTTGTATAACATAGCTCAGCT 59
pHS1, pHS2, pHS3, and pHS4, which were the starting
material for footprint experiments, were obtained by insertion
of the blunt-ended BstEII/ClaI, SalI/EcoRV, EcoRV/PstI, and
ClaI/NcoI fragments, respectively, into the SmaI site of pTZ19
(Pharmacia, Uppsala, Sweden).
Generation of ARE Mutations
Mutations were introduced in ARE-I (2170), ARE-II (2394),
and ARE-III (24200) essentially according to the PCR method
of Higuchi et al. (32). Standard amplification conditions were
30 cycles of denaturation for 1 min at 95 C, annealing for 1
min at 55 C, and extension for 2 min at 72 C. The oligonu-
cleotides that were used for the generation of the different
mutations are listed below. Two different sets of outer prim-
ers were used, one set for ARE-I and -II mutations and a
separate set for ARE-III mutations. Substitutions in comple-
mentary sets of inner primers ARE-I-1, -2; ARE-II-1 and -2;
ARE-III-1 and -2 are underlined (see below). PSA-61-LUC
was used as the template for the first PCR step. In the second
PCR step, appropriate samples of the purified products of the
first amplification reactions were mixed at a 1:1 ratio. The
resulting PCR fragments were cloned and, after sequencing,
exchanged with the corresponding fragment of PSA-61-LUC.
ARE-I and -II outer primers:
forward primer: 59 CCACAAGATCTTTTTATGATGACAG 39
reverse primer: 59 GCTCTCCAGCGGTTCCATCCTCTAG
39
ARE-III outer primers:
forward primer: 59 CTTCTAGGGTGACCAGAGCAG 39
reverse primer: 59 GCAGGCATCCTTGCAAGATG 39
Inner primers:
ARE-I-1: 59 GTAATTGCACATTAGCAATGGGTAACTCTCCC 39
39 CATTAACGTGTAATCGTTACCCATTGAGAGGG 59
ARE-I-2: 59 GTAATTGCATAGTAGCAAAAGGTAACTCTCCC 39
39 CATTAACGTATCATCGTTTTCCATTGAGAGGG 59
ARE-II-1: 59 GGTGCAGGCATAAGGGATGCTCACAATCT 39
39 CCACGTCCGTATTCCCTACGAGTGTTAGA 59
ARE-II-2: 59 GGTGCAGGCATTAGGCAACCTGACAATCT 39
39 CCACGTCCGTAATCCGTTGGACTGTTAGA 59
ARE-III-1: 59 CTCTGGAGCATAATATTTCAACGATTGTC 39
39 GAGACCTCGTATTATAAAGTTGCTAACAG 59
ARE-III-2: 59 CTCTGGAGTAGTATATTACAGCGATTGTC 39
39 GAGACCTCATCATATAATGTCGCTAACAG 59
Transfections
Cells were transfected according to the calcium phosphate
precipitation method essentially as described (33), using 1 3
106 cells per 25-cm2 flask and 5 mg of the appropriate PSA-
LUC construct. After 4 h incubation with the precipitate, the
culture medium was replaced by PBS containing 15% glyc-
erol (incubation for 90 sec at room temperature). Subse-
quently, transfected cells were incubated in culture medium
in the absence or presence of the appropriate hormone for
24 h. Transfections were performed in duplicate. Experiments
were repeated at least three times using two independent
plasmid isolates.
Luciferase Assay
Cells were washed in PBS and lysed in 300 ml lysis buffer (25
mM Tris-phosphate, pH 7.8, 8 mM MgCl2, 1 mM dithiothreitol,
1% Triton X-100, 15% glycerol). Next, 0.1 ml luciferin (0.25
mM) (Sigma, St. Louis, MO)/0.25 mM ATP was added to 0.1 ml
extract, and luciferase activity was measured in a LUMAC
2500 M Biocounter (LUMAC, Landgraaf, The Netherlands).
After a delay of 2 sec (according to supplier), the light emis-
sion was recorded for 5 sec. Luciferase activities were cor-
rected for variations in protein concentrations of the cell
extracts. Luciferase activities and relative induction factors
are expressed as mean and SEM of at least three independent
experiments.
DNAseI Footprint Analysis
Production and purification of AR(DBD) was done as de-
scribed previously (13, 30). Fragments for footprinting were
generated by digestion of pHS1, pHS2, pHS3, and pHS4 with
XbaI and SacI, or with SphI and EcoRI, in order to identify
protected windows on both the upper and lower strand.
Subsequently, fragments were filled in with MMLV-reverse
transcriptase (Boehringer) in the presence of [a-32P]dATP
and isolated from nondenaturing polyacrylamide gel. The
DNaseI footprinting experiments were performed essentially
according to Lemaigre et al. (34). Labeled probe (50,000 cpm)
was incubated with 10–20 pmol AR(DBD) fusion protein for
30 min at 0 C, in the presence of 10 mM ZnCl2. In indicated
cases, a 100-fold excess competitor oligos (consensus ARE
or consensus NF-1; 59-GATCCAGGGAACAGGGTGTTC-
TACG-39, and 59-ATTTTGGCTTGAAGCCAATATG-39, re-
spectively)) was added. Digestion with 0.04 U of DNaseI
(Boehringer) was for 60 sec at 20 C in a final volume of 50 ml.
In the absence of AR(DBD), 0.025 U of DNAseI was used.
After phenol/chloroform extraction and ethanol precipitation,
DNA was dissolved in 5 ml formamide-dye mix (98% form-
amide, 10 mM EDTA, 0.2% bromophenol blue, and 0.2%
xylene cyanol). After heating to 95 C for 2 min and rapid
cooling on ice, the DNA was separated on a denaturing (7 M
urea) 6% polyacrylamide gel. G and (G1A) sequence reac-
tions according to Maxam and Gilbert (35) of the same frag-
ment were run as markers alongside each footprint. After
electrophoresis, gels were fixed, dried, and exposed to x-ray
film.
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Gel Retardation Analysis
The gel retardation experiments were performed as de-
scribed previously (13). Double- stranded oligonucleotides
used in gel retardations:
ARE-I: 59 GATCCTTGCAGAACAGCAAGTGCTAGCTG 39
39 GAACGTCTTGTCGTTCACGATCGACCTAG 59
ARE-II: 59 GATCCAGGGATCAGGGAGTCTCAGG 39
39 GTCCCTAGTCCCTCAGAGTCCTAG 59
ARE-III: 59 TCGACGAGGAACATATTGTATCGAG 39
39 GCTCCTTGTATAACATAGCTCAGCT 59
Shortly, probes were filled in with MMLV-reverse transcrip-
tase in the presence of [a-32P]dATP and subsequently iso-
lated from nondenaturing polyacrylamide gel. Labeled probe,
50,000 cpm, was incubated with AR(DBD) (30 fmol to 2 pmol).
In indicated cases 100-fold excess ARE or NF-1 competitor
oligonucleotides were added. After incubation for 20 min,
samples were run on a 4% nondenaturing polyacrylamide
gel. Subsequently, gels were fixed, dried, and exposed to
x-ray film.
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